Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission

Evidence from an epidemiological study and from animal experiments
  • Heinz Häfner
  • Stephan Behrens
  • Jean De Vry
  • Wagner F. Gattaz
Short Communication

Summary

In a representative sample of 392 first hospital admissions for schizophrenia from a population of 1.5 million we assessed the “true” age of onset by a semistandardized interview “IRAOS”. We demonstrated that the mean age at onset of the disease is 3–4 years higher in females than in males, with the lifetime risk being exactly equal. In males, the rates of onset show a steep increase — starting from school age and reaching their maximum value in the age group 15–24 years — followed by a steady decrease. Females reach the first peak with a clear delay between 20 and 29 years. After the decrease, a second smaller peak is observed consistently in females within the age group 45–49 years and over. After having excluded competing explanations, we hypothesized that the effect of oestradiol on the dopaminergic system enhances the vulnerability threshold, which is lowered again during the menopause. Alternatively, we assumed that testosterone reduces the vulnerability threshold and thus furthers the earlier onset of the disease in males. We tested the hypotheses in three animal models by examining the effect of gonadal hormones on haloperidol-induced catalepsy and on apomorphine-induced stereotypies in both neonatal and adult rats. No clear influence by testosterone was shown. Oestradiol caused a significant reduction of both dopamine-agonist and dopamine-antagonist induced behaviour. The effects were stronger in neonatal rats. Since oestradiol caused the dopamine (DA) receptor affinity for sulpiride to be reduced by a factor of 2.8, we assumed that the behavioural changes due to oestradiol were accounted for by a down-regulation of DA receptor sensitivity. The higher age at onset and the second peak of onsets after menopause in females may therefore be due to a functional effect and possibly also to an additional structural effect of oestrogens already exerted on the development of the brain.

Key words

Schizophrenia Onset of schizophrenia Gender differences in schizophrenia Oestradiol effect on dopamine receptor sensitivity Vulnerability threshold in schizophrenia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bédard P, Langelier P, Villeneuve A (1977) Oestrogens and extrapyramidal system. Lancet II:1367–1368Google Scholar
  2. Bleuler M (1943) Die spätschizophrenen Krankheitsbilder. Fortschr Neurol Psychiatr 15:259Google Scholar
  3. Bleuler M (1972) Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Thieme, StuttgartGoogle Scholar
  4. Chang SS, Renshaw DC (1986) Psychosis and pregnancy. Compr Ther 12:36–41Google Scholar
  5. DiPaolo T, Falardeau P (1985) Modulation of brain and pituitary dopamine receptors by estrogens and prolactin. Prog Neuropsychopharmacol Biol Psychiatry 9:473–480Google Scholar
  6. Fields JZ, Gordon JH (1982) Estrogen inhibits the dopaminergic supersinsitivity induced by neuroleptics. Life Sci 30:229–234Google Scholar
  7. Häfner H (1987) Epidemiology of schizophrenia. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia. Springer, Berlin Heidelberg New York, pp 47–74Google Scholar
  8. Häfner H, Riecher A, Maurer K, Löffler, Munk-Jorgensen P, Strömgren E (1989) How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. Psychol Med 19:903–918Google Scholar
  9. Häfner H, Behrens S, De Vry J, Gattaz WF, Löffler W, Maurer K, Riecher-Rössler A (1991) Warum erkranken Frauen später an Schizophrenie? Nervenheilkunde (in press)Google Scholar
  10. Häfner H, Maurer K, Löffler W, Riecher-Rössler A (1991a) Schizophrenie und Lebensalter. Nervenarzt (in press)Google Scholar
  11. Harris MJ, Jeste DV (1988) Late-onset schizophrenia: an overview. Schizophr Bull 14:39–55Google Scholar
  12. Huber G, Gross G, Schüttler R (1979) Schizophrenie. Verlaufund sozial-psychiatrische Langzeituntersuchungen an den 1945 bis 1959 in Bonn hospitalisierten schizophrenen Kranken. Monographie aus dem Gesamtgebiet der Psychiatrie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  13. Hruska RE (1986) Elevation of striatal dopamine receptors by estrogen: dose and time studies. J Neurochem 47:1908–1915Google Scholar
  14. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychoses. Br J Psychiatry 150:662–673Google Scholar
  15. Labrie F, Beaulieu M, Caron M, Raymond V (1978) The adenohypophyseal dopamine receptors, specificity and modulation of its activity by estradiol. In: Robin C and Harter M (eds) Proc Int Symp on Prolactin, Elsevier, Amsterdam, pp 121–136Google Scholar
  16. Raymond V, Beaulieu M, Labrie F, Boissier JR (1978) Potent antidopaminergic activity of estradiol at the pituitary level of prolactin release. Science 200:1173–1175Google Scholar
  17. Seeman MV, Lang M (1990) The role of estrogens in schizophrenia gender differences. Schizophr Bull 16:185–194Google Scholar
  18. Sovner R, DiMascio A (1978) Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Lipton MA (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1021–1032Google Scholar
  19. Villeneuve A, Cazejust T, Coté M (1980) Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology 6:145–151Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Heinz Häfner
    • 1
  • Stephan Behrens
    • 1
  • Jean De Vry
    • 1
  • Wagner F. Gattaz
    • 1
  1. 1.Central Institute of Mental Health, I5Mannheim 1Germany

Personalised recommendations